Expert Point of View: Robert Jones, MD, PhD


Get Permission

Robert Jones, MD, PhD

Robert Jones, MD, PhD

Formal discussant of this trial, Robert Jones, MD, PhD, of the University of Glasgow, Beatson West of Scotland Cancer Center, Glasgow, Scotland, said: “I think it is clear that programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1)–targeted immunotherapy now has a role for most patients with advanced urothelial cancer. The survival curves were significantly separated at 2 years, and the overall survival data are consistent with previous analyses of this trial.”

“The pembrolizumab [Keytruda] results should increase confidence in the second-line use of the drug and help patients make an informed decision about whether or not to accept this treatment. The results remain in keeping with the possibility of a long immunotherapy survival tail. None of these data support a role for second-line cytotoxics after failure of platinum in preference to a checkpoint inhibitor,” Dr. Jones said. ■

DISCLOSURE: Dr. Jones reported no conflicts of interest.


Related Articles

Pembrolizumab Survival Advantage Upheld in Advanced Urothelial Carcinoma

Joaquim Bellmunt, MD, PhD

Joaquim Bellmunt, MD, PhD

Patients with recurrent urothelial cancer had sustained improvement in overall survival at 2 years after they received second-line treatment with pembrolizumab (Keytruda) vs chemotherapy, according to an updated survival analysis of the phase III KEYNOTE-045 trial ...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.